Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5391019 | 0.86 | SLC6A3 (0.51) | ESR1ESR2SLC6A3HSD17B10KMT2A | |
| SCHEMBL30505635 | 0.85 | SLC6A3 (0.71) | ESR1ESR2SLC6A3HSD17B10KMT2A | |
| SCHEMBL1979275 | 0.85 | SLC6A3 (0.71) | ESR1ESR2SLC6A3HSD17B10KMT2A | |
| SCHEMBL1058373 | 0.85 | SLC6A3 (0.77) | ESR1ESR2SLC6A3HSD17B10KMT2A | |
| SCHEMBL844563 | 0.84 | ESR1 (0.72) | ESR1ESR2SLC6A3HSD17B10KMT2A | |
| SCHEMBL8777320 | 0.84 | SLC6A3 (0.69) | ESR1ESR2SLC6A3HSD17B10KMT2A | |
| SCHEMBL11777918 | 0.83 | SLC6A3 (0.58) | ESR1ESR2SLC6A3HSD17B10KMT2A | |
| SCHEMBL28263594 | 0.82 | HSD17B10 (0.72) | ESR1ESR2SLC6A3HSD17B10KMT2A | |
| SCHEMBL11280439 | 0.82 | KDM4E (0.68) | ESR1ESR2SLC6A3HSD17B10KMT2A | |
| SCHEMBL10499871 | 0.81 | SLC6A3 (0.57) | ESR1ESR2SLC6A3HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601251-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8481595-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481595-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8178675-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178675-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120071526-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071526-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-03-22 | — | — | US | disclosed |
| EP-1988772-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2011-10-26 | — | — | EP | disclosed |
| US-8022249-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022249-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-20070173544-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2007-07-26 | — | — | US | disclosed |
| US-20070173544-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2007-07-26 | — | — | US | disclosed |
| US-20070105955-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2007-05-10 | — | — | US | disclosed |
| US-20070105955-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2007-05-10 | — | — | US | disclosed |
| US-6172062-B1 | ANTISEROTONIN AGENTS; GASTROINTESTINAL DISORDERS; CARDIOVASCULAR DISORDERS; NERVOUS SYSTEM DISORDERS | SYNTEX (USA) LLC | 2001-01-09 | — | — | US | disclosed |
| EP-0207913-B1 | CATECHOL CARBOXAMIDES, PROCESS FOR THEIR PREPARATION, INTERMEDIATES AND A PHARMACEUTICAL PREPARATION | Astra Läkemedel Aktiebolag (SE) | 1990-10-31 | — | — | EP | disclosed |
| EP-0207913-A1 | Catechol carboxamides, process for their preparation, intermediates and a pharmaceutical preparation | Astra Läkemedel Aktiebolag (SE) | 1987-01-07 | — | — | EP | disclosed |
| WO-1986007591-A1 | CATECHOLCARBOXAMIDES, PROCESS FOR THEIR PREPARATION, INTERMEDIATES AND A PHARMACEUTICAL PREPARATION | Astra Läkemedel Aktiebolag (SE) | 1986-12-31 | — | — | WO | disclosed |
| EP-0201575-A1 | NEW PICOLINE DERIVATIVES, PREPARATION PROCESS THEREOF, UTILIZATION THEREOF AND DRUGS CONTAINING THEM. | BYK GULDEN LOMBERG CHEM FAB (DE) | 1986-11-20 | — | — | EP | disclosed |
| WO-1986002646-A1 | NEW PICOLINE DERIVATIVES, PREPARATION PROCESS THEREOF, UTILIZATION THEREOF AND DRUGS CONTAINING THEM | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT M (DE) | 1986-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173544-A1 | Compounds for the treatment of metabolic disorders | CPT1B, GPR119, CPT1A | ESR1 2033/4885ESR2 1023/4885SLC6A3 1497/4885 |
| US-20070105955-A1 | Compounds for the treatment of metabolic disorders | CPT1B, FABP1, CPT1A | ESR1 2486/4885ESR2 1052/4885SLC6A3 1616/4885 |
| US-20120071526-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, CPT1A, FABP1 | ESR1 1509/4885ESR2 610/4885SLC6A3 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.